#### ARC Journal of Pharmaceutical Sciences (AJPS)

Volume 9, Issue 1, 2024, PP 1-9

ISSN 2455-1538(Online)

DOI: https://doi.org/10.20431/2455-1538.0901001

www.arcjournals.org



# Determination of Folic Acid in Pharmaceutical Dosage Forms: A Review

#### Imad Osman Abu Reid

International University of Africa, Sudan

\*Corresponding Author: Imad Osman Abu Reid, International University of Africa, Sudan.

#### 1. Introduction

Folic acid (FA), chemically ispteroyl-L-glutamic acid or N- [4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl) methyl] amino] benzoyl]-L-glutamic acid, it is a member of the B vitamin group. The chemical formula of folic acid is  $C_{19}H_{19}N_7O_6[1]$ . The core of the molecule consists of heterocyclic pterin structure, with a methyl group in the sixth position bound to para-aminobenzoic and glutamic acids so that folic acid presents pteroylglutamic acid (Figure 1). Pterin is composed from pyrimidine and pyrazine rings («pteridine») with substituting keto- and amino groups in the second and fourth positions. Aromatic heterocyclic structures provide an ability for reversible electron-accepting [2,3]. "Folates" is a generic term encompassing folic acid and its derivatives-dihydro-, tetrahydro-, methyl-, formyl-compounds possessing metabolic activity. All folates are inherently conjugated with para-aminobenzoyl-glutamate as mono-, di-, tri-, and polyglutamates [4].

**Figure 1**. The structural formula of folic acid (FA). The FAmolecule consists of three parts: pterine, paminobenzolate and glutamate.

Folic acid as a vitamin which is not produced by natural metabolism; it is obtained from the diet. Most dietary folic acid loses its bioavailability during cooking and food processing. Yet folic acid is often recommended as a supplement when the amount of dietary foliate is not sufficient [5].

Folic acid plays a crucial role in preventing major birth defects known as neural tube defects (NTDs). It is essential for cell replication, growth, and the synthesis of DNA and RNA. Folate helps prevent DNA alterations that can lead to cancer. Both adults and children need folate to produce normal red blood cells and prevent anemia. Additionally, supplementation with folic acid and vitamin B12 has been shown to improve vascular endothelial function in patients with coronary heart disease [6]. In vitro evidence shows that 5-methyltetrahydrofolate, the primary circulating metabolite of folic acid, can increase nitric oxide production and directly scavenge superoxide radicals, which may explain some of its cardiovascular benefits [7].

While most studies on folic acid have focused on heart health, recent findings suggest that folic acid may have antidepressant properties or act as an enhancing mediator for standard antidepressant

treatments. Evidence indicates that elderly individuals with depression have lower folate levels than their non-depressed peers. Supplementing with folate might reduce the incidence of depression in the elderly [8,9]. Folate deficiency is a common cause of anemia, with subtle signs such as diarrhea, loss of appetite, weight loss, weakness, a sore tongue, headaches, heart palpitations, and irritability. Additionally, a high risk of giving birth to children with NTDs is associated with women with type I diabetes, with epilepsy or who are under carbamazepine or antifolate medication [10]. For the sake of reducing the risk of NTDs, supplementation of folic acid has been recommended before and during the first three months of pregnancy [11].

The body absorbs folic acid from supplements and fortified foods better than folate from naturally occurring foods. The recommend daily intake of dietary folate equivalents (DFEs) from food or vitamin sources is given in Table 1. The recommended daily dose of folic acid depends on the patient's history of birth abnormalities; the recommended preventative daily allowance of folic acid for women with no prior history of birth defects dose is 4.0 mg per day starting at least 30 days before conception and continuing throughout the first trimester of pregnancy [12].

Age	Recommended amount		
0–6 months	65 mcg dietary folate equivalent (DFE)		
7–12 months	80 mcg DFE		
1–3 years	150 mcg DFE		
4–8 years	200 mcg DFE		
9–13 years	300 mcg DFE		
14–18 years	400 mcg DFE		
19+ years	400 mcg DFE		
During pregnancy	400–800 mcg DFE		
During lactation	500 mcg DFE		

Table 1. The recommended daily intake of folic acid

Development of an appropriate and suitable methodfor quantitative pharmaceutical analysis is very significant. The subsequentmethod validation is obligatory to prove method reliability and it is carriedout as an integral part of quality control. The choice of proper instrumentalmethod depends on affordable equipment and the physicochemical properties of the analytes.

To the best of our knowledge, there are no published review articles on the analytical methods for determining folic acid in pharmaceutical dosage forms. This scientific literature review provides a comprehensive overview of the advancements in evaluating folic acid in pharmaceutical dosage forms from 2000 to 2024. This review categorizes the data according to the analytical methods used, facilitating a quick understanding of the different approaches employed in studying binary mixtures of azole antifungals and corticosteroids. By providing detailed insights from various published studies, this structured presentation enables pharmaceutical researchers and professionals to easily locate pertinent information about the analytical techniques relevant to their research or work.

# 2. METHODS OF ANALYSIS

## 2.1. Official Pharmacoepial Methods

The British Pharmacopeia (BP) [13] monographs described high-performance liquid chromatography (HPLC) for the determination of folic acid in injections, tablets and oral solution.

The chromatographic method for the determination of the injections; involves using ( $C_{18}$ , 20 cm x 4.6 mm, 10  $\mu$ m) column and 4 volumes of acetonitrile, 6 volumes of methanol and 90 volumes of 0.01 M sodium acetate, adjusted to pH 4.5 withacetic acid as mobile phase. The mobile phase is pumped at rate of 1.2 mL per minute and the analyteis monitored at 280nm.

The chromatographic conditions for oral liquid employs ( $C_{18}$ , 25 cm x 4.6 mm, 5µm) column and a two components mobile phase made of: mobile phase A: 10 volumes of methanol and 90 volumes of asolution containing 1.116 w/v% of potassium dihydrogenphosphate and 0.55% w/v of dipotassium hydrogen phosphate and mobile phase B methanol. The mobile phase is delivered in a gradient fashion; where 100% of mobile phase A was pumped for 45 minutes, then its composition was brought to 50% for within 2 minutes and kept as such for 14 minutes, then taken back to 100% A

within 1 minute and kept as such for 15 minutes. The mobile phase pumped at rate of 0.6 mL per minute and the analyteis monitored at 280nm.

The chromatographic method for the determination of the tablets form involves using ( $C_{18}$ , 20 cm x 4.6 mm, 10  $\mu$ m) column and 7 volumes of acetonitrile and 93 volumes of 0.05M potassium dihydrogen orthophosphate adjusted to pH 6.0 with 5M sodiumhydroxide. The mobile phase is pumped at rate of 2 mL per minute and the analyteis monitored at 283nm.

According to the United States Pharmacopeia (USP)[14]; both the folic injection and tablet dosage are analyzed using the same chromatographic conditions, utilizing a ( $C_{18}$ , 25 cm x 4.6 mm, 5µm) and mobile phase prepared by transferring 35.1 g of sodium perchlorate and1.40 g of monobasic potassium phosphate to a 1-Lvolumetric flask followed by 7.0 mL of 1 N potassium hydroxideand 40 mL of methanol, the mixture is then diluted with water to volume, mixed well and adjusted to a pH of 7.2 with 1 N potassium hydroxide orphosphoric acid. The mobile phase pumped at rate of 1.0 mL per minute and the analyte was monitored at 254nm.

The USP method for oral liquid employs ( $C_{18}$ , 10 cm x 4.6 mm, 5µm) column maintained at 40 ° C and a two components mobile phase made of mobile phase A:50 mM monobasic potassium phosphateadjusted with phosphoric acid to a pH of 2.5and mobile phase B methanol. The mobile phase is delivered in a gradient fashion; the gradient program starts with 95% of mobile phase Akept as such for 2 minutes; followed by a gradient two steps, one from 95 to 90% over 8 minutes and another from 90% to 85% over 15 minutes, the two steps were followed by a small gradient segment from 85% to 65% over one minute and finally the composition was brought again to 95% mobile phase A. The mobile phase was pumped at rate of 1.0 mL per minute and the analyte was monitored at 280nm.

## 2.2. Spectroscopic Methods

UV-Vis spectroscopy is an analytical method for qualitative and quantitative determination of compounds containing chromophores that absorb characteristic wavelengths of ultraviolet (UV) or visible light. According to the Beer–Lambert law, absorption is related to the concentration of the sample. In addition to its simplicity, it is characterized by simple sample preparation, low cost, and relatively short analysis time.

Analytical chemists encounter significant challenges when analyzing and ensuring the quality of analytes that lack a chromophore system, are present in very low concentrations, or exist within complex matrices using direct spectrophotometry. Consequently, they turn to alternative approaches such as chemical derivatization, derivative spectroscopy, or chemometric techniques to increase the selectivity or sensitivity of the method.

#### 2.2.1. Direct UV Methods

The content of folic acid in tablets was determined by direct measurement of the absorbance of its solution in 0.01 M NaOH at 255 nm using 0.01 M NaOH as a blank. The method was validated and proved to be have good accuracy, precision and low limit of quantitation (LOQ). The linear range of the method was  $10\text{-}50\mu\text{g/mL}$  [15].

Another method was reported for direct spectrophotometric determination of folic acid in tablets. The method based on measuring the absorbance of the folic acid solution in phosphate buffer pH 9.0 at 282.5 nm. The method was confirmed to be accurate and precise, the linear range of the method was 1.00 and  $17.5 \,\mu g/mL$  [5].

Folic acid in tablets was also determined in the presence of pteroic acid, glutamic acid, aminobenzoic acid, and other products of degradation of folic acid by measurement of its solution in 0.1 M sodium carbonate at 285 nm. The linear range of the method was 1-25  $\mu$ g/mL [16].

Direct spectrophotometric determination of folic acid in tablets was carried out by measuring the absorbance of the aqueous solution at 250 nm against water as a blank. The method shown to be accurate, precise and linear over the range of 5-30 µg/mL [17].

## 2.2.2. Derivative Spectrophotometric Methods

First order derivative spectrophotometric method was used for the determination of folic acid in different pharmaceutical formulations, using 0.1 MNaOH as solvent, spectrophotometric

measurements were made at the zero crossing point wavelength 393 nm. The method is shown to be simple, selective, and robust. Good linearity was achieved over the range of  $1.80 - 2.85 \,\mu\text{g/mL}$  [18].

Three derivative based spectrophotometric methods were reported for the determination of folic acid, para-aminobenzoic acid and, pteroic acid [19]. The first method is a ratio difference spectro photometric method (RDSM) which depends on measuring the difference value in the ratio spectrum, where the difference between 291 and 313 nm was used for the determination of folic acid, while the difference between 305 and 319 nm was selected for the estimation of para-aminobenzoic acid; on the other hand, pteroic acid can be determined using the first derivative of ratio spectra spectro photometric method at 262 nm. The second method was a double-divisor spectrophotometric method (DDSM); this method is based on using the ratio spectrum obtained by the division of the spectrum of ternary mixture (folic acid and para-aminobenzoic acid and, pteroic acid) by the spectrum of binary mixture containing two of the three mentioned components, and in this method, folic acid, para-aminobenzoic acid, and pteroic acid were measured at 242, 313, and 258 nm, respectively. The third method was a mean-centering of ratio spectra spectrophotometric method (MCR); in this method, folic acid, para-aminobenzoic acid, and pteroic acid can be measured using the mean-centered second ratio spectra amplitudes at 317–318 (peak to peak), 264–265 (peak to peak), and 232 nm, respectively.

## 2.2.3. Colorimetric Methods

Two colorimetric method were proposed for determination of Folic acid in pharmaceutical formulations and bulkdosage forms. The first methodwas based on the formation of colored species on binding of folic acidwith sodium nitroprusside and ammonia reagent to produce a dark yellow colored chromogen was measured at 390 nm, while in the second method the complex is formed between MBTH and ferric chloride and the green colored chromogen was measured at 690 nm. The two methods were linear over the range  $10-50 \, \mu g/mL \, [20]$ .

Folic acid in tablet and injection dosages was determined colorimetrically by its reduction to 2,4,5-triamino-6-hydroxypyrimidine (TAHP) using zinc dust in an acidic environment (4N HCl) with heating for 45 minutes at 35°C. The reduction product was then treated with ninhydrin to form a stable purple complex. This complex has an absorbance maximum at 555 nm and follows Beer's law within the concentration range of 4.5- 45 µg/mL [21].

Three spectrophotometric methods were developed for the determination of folic acid in its pure form or pharmaceutical preparations [22]. These methods are based on the probable diazotization of paminobenzoylglutamic acid, which is obtained after the reductive cleavage of folic acid using zinc and concentrated hydrochloric acid. This is followed by coupling with different reagents to produce measurable colored products:

• Coupling with iminodibenzyl(IDB) yields a violet product, measurable at 580 nm.

The reaction carried by adding 2 ml of 5 M hydrochloricacid, followed by the addition of 1 mlof 2% NaNO<sub>2</sub>. To this solution, 1.5 ml of 2% sulfamic acid was added along with 2 ml of 0.5% IDB and 3 ml of alcoholto the sample in a 25 mL volumetric flask. The solution was heated in aboiling water bath for 5 min, cooled and diluted to themark with 1:1 (v/v) H<sub>2</sub>SO<sub>4</sub>.

• Coupling with 3-aminophenol (AMP) produces an orange-yellow product, measured at 460 nm.

The reaction carried by adding 2 ml of 5 M hydrochloric acid, followed by the addition of 2 ml of 1% NaNO<sub>2</sub> and 2 ml of 2% sulfamic acid to the sample in a 25 mL volumetric flask. The solution was mixed with 2 mlof 1% 3-aminophenol, heated in a boiling water bath for 5 min, cooled, followed by the addition of 3 ml of 5 MHCl, swirled, and diluted with water to the mark.

• Coupling with sodium molybdate and pyrocatechol results in a pale red product, measured at 490 nm.

After diazotization as mentioned above,2 ml of 8% sodium molybdate was used along with 1.5 ml of 0.4% pyrocatechol. The solution was swirledwell, heated in a boiling water bath for 5 min, and cooled, the solution was diluted and with  $1:1 (v/v)H_2SO_4$  up to the markin a 25 mL volumetric flask.

Two kinetic spectrophotometric methods (rate data and fixed time method) have been developed for the determination of folic acid (FA) in bulk and pharmaceutical Formulations [23]. The methods

based on the oxidation of FA by Fe(III) in sulfuric acid medium. Fe(III) subsequently reduces to Fe(II) which is coupled with potassium ferricyanide to form Prussian blue.

The rate method involves addition of ammonium ferric sulfate solution (3.0×10-3 M) followed by 1.5 mL of potassium ferricyanide solution (2.5×10-3 M) to aliquot volumes of the drug solution in different 10 mL and then diluted to the volume with double distilled water at 25°C. The content of mixture of each flask was mixed well and the increase in absorbance at 725 nm was recorded as a function of time over 5–20 min against reagent blank treated similarly. The rate data of the reaction at different concentrations was obtained from the slope of the tangent to absorbance time curves. The calibration graphs were constructed by plotting the logarithm of the rate data of the reaction versus logarithm of molar concentration of FA.

The rate method involves addition of ammonium ferric sulfate solution  $(3.0\times10\text{-}3 \text{ M})$  followed by 1.5 mL of potassium ferricyanide solution  $(2.5\times10\text{-}3 \text{ M})$  to aliquot volumes of the drug solution in different 10 mL and then diluted to the volume with double distilled water at 25°C. The content of mixture of each flask, was mixed well and the absorbance of each sample solution at preselected fixed time (15 min) was accurately measured and plotted against the final concentration of the FA.

A spectrophotometric method has been described for estimating folic acid (vitamin B9) in pharmaceutical formulations. This method involves the reaction of folic acid with 1,2-naphthoquinone-4-sulphonate (NQS) in an alkaline medium (NaOH/NaHCO<sub>3</sub>buffer, pH 11), producing a deep yellow compound. The method follows Beer's law for folic acid concentrations ranging from  $0.75 - 10.5 \,\mu\text{g/mL}$  at 436 nm [24].

A spectrophotometric method for determining folic acid (FA) in pharmaceutical preparations. The method involves the initial oxidation of folic acid by aqueous potassium permanganate in an alkaline medium, followed by the addition of 4-nitro aniline. After diluting to the mark with water, the solution's absorbance was measured at 374 nm. The method exhibited linearity over the concentration range of 1-21  $\mu$ g/mL [25].

A spectrophotometric technique for measuring folic acid in both pure and pharmaceutical forms has been outlined. This method involves the oxidation of pyrocatechol with iron (III) in an acidic environment, which then reacts with folic acid (FA) to form a stable, water-soluble orange compound. This compound has a maximum absorption at 350 nm when compared to the blank reagent. The charge transfer complex was analyzed under optimal conditions, and the titration graph demonstrated linearity within the range of 0.5-25 µg/mL [26].

# 2.3. Separation Methods

# 2.3.1. High-Performance Liquid Chromatographic Methods (HPLC)

HPLC is particularly well-suited for assessing the purity and quality of pharmaceutical preparations, especially when gas-liquid chromatography (GLC) is unsuitable due to the insufficient thermal stability or low volatility of the components. As a result, HPLC is favored over GLC for product quality control in most pharmaceutical companies and is included in most international pharmacopeias. The development of highly selective adsorbents and advancements in the sensitivity of flow-through spectrophotometric, fluorimetric, and electrochemical detectors have further boosted the use of HPLC in pharmaceutical analysis.

Reversed-phase high-performance liquid chromatography (RP-HPLC) has been widely utilized for quantifying folic acid in different matrices. Most of the reported methods employed isocratic elution using a reversed-phase column ( $C_8$  or  $C_{18}$ ) and mobile phases composed of organic solvent and buffers mixtures adjusted to specific pH levels.

Although all the reported methods have been validated, none have been systematically developed to justify the experimental conditions used. Moreover, the full potential of HPLC techniques has not been utilized in these methods to develop a stability-indicating method. This is crucial given the nature of folic acid, which degrades readily and is highly sensitive to environmental factors such as heat, UV light, and oxygen[27]. Description of the reported HPLC methods is given in Table 2.

**Table 2:** HPLC methods used for the analysis folic acid

1   folic acid in bulk and tablet   (250 x 4.6 mm, 5 μm)   (250 x 4.6 substances in tablets   (250 x 4.6 mm, 5 μm)   (300 x 4.0 mm, 10 μm)   (300 x 4.0 mm, 10 μm)   (300 x 4.0 mm, 5 μm)   (300 x 4.0 mm, 3 μm)   (300 x 4.0 mm,	No	Matrix	Column	Mobile phase	Determinatio	λ(nm)	(Ref)
Tolic acid in bulk and tablet dosage form   C18							
Dulk and tablet   dosage form   S µm   Orthophosphate buffer: methanol   (70:30 \times v). The flow rate was maintained at 0.6mL/min   multivitamin mineral preparations   To   S µm	1	folic acid in	C	0.05M notassium dihydrogan		212	[28]
dosage form   mm, 5 μm   (70:30 v/v). The flow rate was maintained at 0.6mL/min	1				10-30	212	[20]
Colic acid and its related substances in tablets   C350 x 4.6 mm, 5 μm)   To 13 mL of 10% acetonitrile. The solution is adjusted by the additionof potassium disordium hydrogen phosphate buffer (11.16 multivitamin mineral preparations   C18 mm, 10μm)   To 13 mL of 10% acetonitrile. The solution is adjusted by the additionof potassium dihydrogen phosphate buffer (11.6 mm)   To 13 mL of 10% aqueous tetrabutylammoniumhydroxide is added, 840 mL of water, 50mg of ethylenediaminetetracetic acid disodium salt (EDTA), and160 mL of acetonitrile. The solution is adjusted by the additionof potassium dihydrogen phosphate to pH 7.6   To 13 mL of 10% acetonitrile. Ol.14M   To 28 mm, 20μm   To 18 mm, 5 μm   To 18 mm, 18 mm   To 18 mm   T			`				
Continue		Goodge Tollin	, & p)				
related substances in tablets   30°C   mm, 5 μm   30°C   mm, 5 μm   multivitamin-mineral preparations   folic acid in multivitamin-mineral preparations   folic acid in multivitamin and minerals preparations   folic acid in preparations   folic acid in multivitamin and minerals preparations   folic acid in pharmaceutical preparations   folic acid in pharmaceutical (150 mm × 3 μm)   folic acid in pharmaceutical (150 mm × 3 μm)   folic acid in pharmaceutical (150 mm × 3 μm)   folic acid in tablets   folic acid acid acid acid acid acid acid ac	2	folic acid and its	C <sub>8</sub>		0.01 - 5.91	280	[29]
tablets   30°C   to pH=6.4 with dilute orthophosphoric acid (12:88, v/v %). The flow rate was maintained at 0.7 mL/min     3   folic acid in multivitamin-mineral preparations   mm, 10μm   mineral preparations   mm, 10μm   mineral preparations							
tablets   30°C   to pH=6.4 with dilute orthophosphoric acid (12:88, v/v %). The flow rate was maintained at 0.7 mL/min     3   folic acid in multivitamin-mineral preparations   mm, 10μm   mineral preparations   mm, 10μm   mineral preparations		substances in	mm, 5 μm)	hydrogen phosphate with pH adjusted			
Maintained at 0.7 mL/min   To 13 mL of 10% aqueous   O-5   280   [30]		tablets	30°C	to pH=6.4 with dilute orthophosphoric			
To 13 mL of 10% aqueous tetrabutylammoniumhydroxide is added, 840 mL of water, 50mg of ethylenediaminetetraacetic acid disodium salt (EDTA), and 160 mL of acetonitrile. The solution is adjusted by the additionof potassium dihydrogen phosphate to pH 7.6   Folic acid in multivitamin and minerals preparations   To 18 mL of 10% acetonitrile: 0.014M				acid) (12:88, $v/v$ %). The flow rate was			
multivitamin mineral preparations   (300 x 4.0 mm, 10μm)   tetrabutylammoniumhydroxide is added, 840 mL of water, 50mg of ethylenediaminetetraacetic acid disodium salt (EDTA), and 160 mL of acetonitrile. The solution is adjusted by the additionof potassium dihydrogen phosphate to pH 7.6							
mineral preparations	3				0-5	280	[30]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$							
disodium salt (EDTA), and 160 mL of acetonitrile. The solution is adjusted by the addition of potassium dihydrogen phosphate to pH 7.6   4   folic acid in multivitamin and minerals preparations   (300 x 3.9 mm, 20μm)   (300 x 3.9 mm, 20μm)   (300 x 4.6 mm, 5 μm)   (300 x 4.6 mm, 3.5 μm)   (300 x 4.6 mm, 5 μm)   (300 x 4.6 mm)   (300			mm, 10μm)				
decentified addition of potassium dihydrogen phosphate to pH 7.6		preparations		1			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$							
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							
Folic acid in multivitamin and minerals preparations   C18 (300 x 3.9 mm, 20μm)   Tolic acid in tablets   C18 (300 x 4.6 mm, 5 μm)   30°C   Tolic acid in tablets   C18 (150 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 3.5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C18 (250 x 4.6 mm, 5 μm)   Tolic acid in tablets   C10 x 2.1 acid salt made pH 2.5 with phosphoric acid in the ratio of 10:90 v/v. The Flow   C140   C16   C160 x 2.1 acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in the ratio of 10:90 v/v. The Flow   C160 x 2.1 acid and acid in							
multivitamin and minerals preparations   (300 x 3.9 mm, 20μm)   (300 x 4.6 mm, 5 μm)   (300 x 4.6 mm, 5 μm)   (300 x 4.6 mm, 5 μm)   (150 mm × 3 mm)   (150 mm		C 1' ' 1 '			5.20	202	[21]
and minerals preparations $0.1\% \text{ mm}$ , $0.1\%  $	4				5-20	283	[31]
$\begin{array}{ c c c c c }\hline preparations & & & & & & & \\ folic acid in & & & & & \\ tablets & & & & & \\ (300 \text{ x } 4.6 \\ mm, 5  \mu\text{m}) & & & \\ 30^{\circ}\text{C} & & & \\ \hline \end{array}$				· · · · · · · · · · · · · · · · · · ·			
Tolic acid in tablets   C <sub>18</sub> (300 x 4.6 mm, 5 μm) 30°C   C <sub>18</sub> (150 mm × 3 mm, 5 μm) 30°C   So ml of a solution of 4.3 g sodium hexane sulfonate in 100 ml acetonitril/water 50/50, adjusted to pH 2.65 with glacial acetic acid in 1000 ml of a mixture of 23.4/76.6 methanol/water.   C <sub>18</sub> (150x4.6 mm, 3.5 μm)   S.2 (50:50 v.v), at flow rate 1.0 mL/min   C <sub>18</sub> (250 x 4.6 mm, 5 μm)   The flow rate of 1.0 mL/min.   C <sub>18</sub> (100 x 2.1 mm, 1.7μm)   C <sub>18</sub> (100			ιιιιι, 20μιιι)	10:84 V/V			
tablets $(300 \times 4.6 \text{ mm, 5 } \mu\text{m})$ $30^{\circ}\text{C}$ $(150 \text{ mm} \times 3 \text{ preparations})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm, 5 } \mu\text{m})$ $(150 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm})$ $(150 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm})$ $(150 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm} \times 3 \text{ mm})$ $(150 \text{ mm} \times 3 $	-5		C	0.1% y/y trifluoroacatic acid and	1.5	200	[32]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	)				1-3	290	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		tablets		accionime at ratio (00.20 V/V)			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							
preparations mm, 5 $\mu$ m) 100 ml acetonitril/water 50/50, adjusted to pH 2.65 with glacial acetic acid in 1000 ml of a mixture of 23.4/76.6 methanol/water.  7 folic acid in tablets (150x4.6 mm, 3.5 $\mu$ m) mL/min  8 folic acid in tablets (250 x 4.6 mm, 5 $\mu$ m) mL/min  8 folic acid in tablets (250 x 4.6 mm, 5 $\mu$ m) The flow rate of 1.0 mL/min.  9 folic acid in tablets (100 x 2.1 mm, 1.7 $\mu$ m) acid in the ratio of 10:90 v/v. The Flow	6	folic acid in		50 ml of a solution	0.6–12	PDA	[33]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		pharmaceutical	$(150 \text{ mm} \times 3)$	of 4.3 g sodium hexane sulfonate in		detector	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		preparations	mm, 5 μm)	100 ml acetonitril/water 50/50,			
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$							
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$				I.			
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	7				3.22-12.86	240	[34]
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		tablets	`	` //			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		C 1: . 1 :			5.000	200	F2.53
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	8				5-200	290	[35]
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		tablets	`				
9 folic acid in tablets (100 x 2.1 mm, 1.7μm) Acetonitrile :0.005 M hexane sulfonic acid salt made pH 2.5 with phosphoric acid in the ratio of 10:90 v/v. The Flow				The now rate of 1.0 mL/min.			
tablets (100 x 2.1 acid salt made pH 2.5 with phosphoric mm, 1.7µm) acid in the ratio of 10:90 v/v. The Flow	Q	folic acid in		Acetonitrile :0.005 M heyane sulfonic	20-140	210	[36]
mm, 1.7μm) acid in the ratio of 10:90 v/v. The Flow	′				20 170	210	[30]
		111010					
rate was 0.4 ml/min			,,)	rate was 0.4 ml/min			

## 2.3.2 Thin-layer Chromatographic Methods

In the last two decades' thin layer chromatography (TLC) has become one of the most useful chromatographic methods, especially for qualitative analysis and preparative separations. Quantitative determination by TLC has never been as popular as gas chromatography and high-performance liquid chromatography, due to problems with sample applications, development and evaluation. However, due to the recent developments in instrumentation for TLC will which lead to a general improvement in accuracy and precision, TLC now is increasingly being used for the quantitative determination of drugs determination in tablets, capsules, solutions, ointments, and many other formulation types [37].

A TLC-densitometric method was developed for the separation and quantification of folic acid in the presence of its two impurities (photodegradation products), pteroic acid and para-aminobenzoic acid, on TLC silica gel  $60 \, F_{254}$  plates. The developing system used was methanol:isopropanol:water: acetic acid (9:0.5:0.5:0.2, v/v). The separated bands were then measured densitometrically at 280 nm. The

method exhibited linearity over the ranges of 0.4-4  $\mu$ g/mL for folic acid, 0.1-1.5  $\mu$ g/mL for para-aminobenzoic acid, and 0.2-1.8  $\mu$ g/mL for pteroic acid [19].

A high-performance thin layer chromatographic (HPTLC) method has been developed for identification and quantification of folic acid. The chromatography was performed on 20 cm  $\times$  10 cm silica gel 60F<sub>254</sub> HPTLC plates. Plates were developed to a distance of 90 mm in a 20 cm  $\times$  10 cm vertical chamber containing 40 mL mobile phase (isopropyl alcohol—ethylacetate—water—a queous ammonia, 4 + 2 + 2 + 1 v/v/v/v). The spots detection was carried at 289 nm. The method was linear over the range of 25 -70 µg/mL [38].

A High Performance Thin Layer Chromatography (HPTLC) method was developed for analyzing folic acid in tablets. The separation was performed on pre-coated HPTLC silica gel 60 F254 glass plates using a mobile phase of ethyl acetate: methanol mixture (15:15:0.5 v/v/v). Detection was carried out at a wavelength of 280 nm, and the method exhibited a linear range of 317.19–761.25 ng/spot [39].

#### 3. CONCLUSION

This study provides a thorough overview of commonly employed methods for analyzing folic acid. It encompasses a wide range of methods described for these compounds in various bulk or pharmaceutical dosage forms. The review spans from 1981 to the present day, offering a comprehensive analysis of the literature on this topic. The primary distinction among existing methods lies between chromatographic and non-chromatographic techniques. As depicted in Figure 2, chromatographic methods are predominant, constituting 40% of the utilized techniques, followed by colorimetric methods at 36% with direct UV and thin-layer chromatographic methods (TLC) at 12% each.




Figure 2. Pie chart indicating the % ratio of the analytical methods used for the determination of folic acid

#### REFERENCES

- [1] Molloy, A.M. Folate bioavailability and health. Int. J. VitamNutr. Res. 2002, 72, 46–52, doi:10.1024/0300-9831.72.1.46.
- [2] Feirer, N.; Fuqua, C. Pterin function in bacteria. Pteridines 2017, 28. doi:10.1515/pterid-2016-0012.
- [3] Mahendran, R.; Thandeeswaran, M.; Kiran, G.; Arulkumar, M.; Ayub Nawaz, K.A.; Jabastin, J.; Janani, B.; Anto Thomas, T.; Angayarkanni, J. Evaluation of pterin, a promising drug candidate from cyanide degrading bacteria. Curr. Microbiol. 2018, 75, 684–693, doi:10.1007/s00284-018-1433-0.
- [4] Thöny, B.; Auerbach, G.; Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 2000, 347, 1–16.
- [5] Matias, R., Ribeiro, P., Sarraguça, M., & Lopes, J. (2014). A UV spectrophotometric method for the determination of folic acid in pharmaceutical tablets and dissolution tests. Analytical Methods, 6(9), 3065-3071.
- [6] Chambers, J.C., Ueland, P.M., and Obeid, O.A. 2000. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasmahomocystein. Circulation, 102(20):2479-83.

- [7] Moat, S.J., Lang, D., and McDowell, I.F. 2004. Folate, homocystein, endothelial function and cardiovascular disease. J. Nutr. Biohem. 15(2): 64:79.
- [8] Alpet, M.M. Silva, R.R., and Pouget, E.R. 2003. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J. Clin. Psychopharmacol, 23(3):309-13.
- [9] Green, N. S. (2002). Folic acid supplementation and prevention of birth defects. The Journal of nutrition, 132(8), 2356S-2360S
- [10] French, A. E., Grant, R., Weitzman, S., Ray, J. G., Vermeulen, M. J., Sung, L., Greenberg, M., & Koren, G. (2003). Folic acid food fortification is associated with a decline in neuroblastoma. Clinical Pharmacology & Therapeutics, 74(3), 288-294.
- [11] McStay, C., Prescott, S., Bower, C., & Palmer, D. (2017). Maternal folic acid supplementation during pregnancy and childhood allergic disease outcomes: a question of timing? Nutrients, 9(2), 123.
- [12] Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998.
- [13] The British Pharmacopoeia, HM Stationery Office, London, 2022. Volume III. 701-704.
- [14] The United States Pharmacopoeia, The National Formulary, 26th ed., U.S. Pharmacopeial Convention, Washington, DC, 2024. Electronic version.
- [15] Elkhazein TA, Abdeljabar TA, Abdelrahman AN, Adam ME, Shantier SW. Development and validation of UV-spectrophotometric method for the determination of folic acid in bulk and tablet dosage forms. Journal of Applied Pharmaceutical Research. 2022 Jun 30;10(2):19-23.
- [16] Modupe O, Maurras JB, Diosady LL. A spectrophotometric method for determining the amount of folic acid in fortified salt. Journal of Agriculture and Food Research. 2020 Dec 1; 2:100060.
- [17] Throat DB, Pawar K, Ashwini P. Method development and validation of folic acid by UV-Visible spectroscopy. International Journal of Pharmaceutical Sciences and Research. 2015 Jul 1;6(7):3088.
- [18] Ribeiro MV, Melo ID, Lopes FD, Moita GC. Development and validation of a method for the determination of folic acid in different pharmaceutical formulations using derivative spectrophotometry. Brazilian Journal of Pharmaceutical Sciences. 2016 Dec;52(4):741-50.
- [19] Ali NW, Abdelwahab NS, Abdelrahman MM, El-Zeiny BA, Tohamy SI. Development and validation of spectrophotometric and high-performance thin-layer chromatographic methods for the determination of folic acid in the presence of its impurities (degradation products). Journal of Planar Chromatography. 2018 Oct; 31:367-76.
- [20] Settaluri VS, Felice CS, Vemulapally S, Valluru S. Novel spectroscopic methods for determination of folic acid in pharmaceutical formulations. Biomedical and Pharmacology Journal. 2015 Feb 16;2(2):317-20.
- [21] Ramana Rao G, Mahajan SN, Kanjilal G, Mohan KR. New colorimetric method for folic acid assay in dosage forms. Journal of the Association of Official Analytical Chemists. 1977 May 1;60(3):531-5.
- [22] Nagaraja P, Vasantha RA, Yathirajan HS. Spectrophotometric determination of folic acid in pharmaceutical preparations by coupling reactions with iminodibenzyl or 3-aminophenol or sodium molybdate–pyrocatechol. Analytical biochemistry. 2002 Aug 15;307(2):316-21
- [23] Khateeb M, Elias B, Rahal FA. New kinetic spectrophotometric method for determination of folic acid in pharmaceutical formulations. International Letters of Chemistry, Physics and Astronomy. 2015 Jan 1; 50:169-78.
- [24] Al-Araji RR, Mashkour MS, Al-Mulla EA. Spectrophotometric determination of vitamin folic acid B9 in some drugs using 1, 2-naphthoquine-4-sulphonate (NQS). Nano Biomedicine and Engineering. 2017 Sep 1;9(3):208-13.
- [25] Al Tikrity RS, Al Rashidy AA. Spectrophotometric determination of Folic acid (B9) by oxidative Coupling Reaction with 4-nitro-aniline. Tikrit Journal of Pure Science. 2022;27(6):28-32.
- [26] Sager AG, Katoof ZR, Radh RS. Determination of Folic Acid in both Pure and Pharmaceutical Preparations via Oxidative Coupling Reaction. Iraqi Journal of Science. 2023 Aug 30:3735-47.
- [27] Gazzali AM, Lobry M, Colombeau L, Acherar S, Azaïs H, Mordon S, Arnoux P, Baros F, Vanderesse R, Frochot C. Stability of folic acid under several parameters. European Journal of Pharmaceutical Sciences. 2016 Oct 10;93:419-30.
- [28] Savitha K, Ravichandran S. Method Development and Validation for Simulataneous Estimation of Biotin and Folic Acid in Bulk and Tablet dosage form by RP-HPLC. Research Journal of Pharmacy and Technology. 2020 Nov 1;13(11):5289-92.

- [29] Grncharoska K, Todevska EL, Spirevska IS, Stoimenova TB, Achevski B, Anastasova L, Petkovska R. A stability-indicating HPLC method for determination of folic acid and its related substances in tablets. Macedonian Pharmaceutical Bulletin. 2022 Jan 1;68(1).
- [30] Holcomb IJ, Fusari SA. Liquid chromatographic determination of folic acid in multivitamin-mineral preparations. Analytical Chemistry. 1981 Apr 1;53(4):607-9.
- [31] Klaczkow GA, Anuszewska EL. The use of HPLC method for determination of the folic acid in multi-component vitamin preparations. ActaPoloniaePharmaceutica. 2000;57(4):257-60.
- [32] El-Leithy ES, Abdel-Bar HM, El-Moneum RA. Validation of high performance liquid chromatographic method for folic acid assay. International Journal of Pharmaceutical Science Invention. 2018;7(1):1-5.
- [33] Deconinck E, Crevits S, Baten P, Courselle P, De Beer J. A validated ultra-high pressure liquid chromatographic method for qualification and quantification of folic acid in pharmaceutical preparations. Journal of pharmaceutical and biomedical analysis. 2011 Apr 5;54(5):995-1000.
- [34] Alagić-Džambić L, Dacić M, Beganović L, Džambić M. RP-HPLC Method of the Estimation of Folic Acid in Tablets. Chemistry Research Journal. 2020; 5(6):163-166
- [35] Adejumo OE, Badmus FA, Oluboba MA, Bamiro OA. High-Performance Liquid Chromatographic Determination of Folic Acid Content in Pharmaceutical Formulations marketed in Southwest Nigeria. The Nigerian Journal of Pharmacy. 2023 Oct 8;57(2):624-632. https://doi.org/10.51412/psnnjp. 2023.22.
- [36] Sreeram VA, Basaveswara Rao MV. Validated and stability indicating ultra-high pressure liquid chromatographic method for folic acid in pharmaceutical preparation. Inter. J. Chem. Stud. 2013;1(1):17-27.
- [37] Cimpoiu C, Hodisan S. Quantitative thin layer chromatography analysis by photodensitometry. Reviews in Analytical Chemistry. 2002; 21(1): 55 -75. https://doi.org/10.1515/REVAC.2002.21.1.55
- [38] Dongre VG, Bagul VA. New HPTLC method for identification and quantification of folic acid from pharmaceutical dosage preparations. JPC–Journal of Planar Chromatography–Modern TLC. 2003 Apr; 16:112-6.
- [39] Sempombe J, Manyanga VP, Masota N, Lutta E, Nyamweru BC, Kaale E, Layloff T. A Thin Layer Chromatography Densitometric Method for Assay of Folic Acid in Tablets. East and Central African Journal of Pharmaceutical Sciences. 2015;18(2):37-42.

**Citation:** Imad Osman Abu Reid. Determination of Folic Acid in Pharmaceutical Dosage Forms: A Review. ARC Journal of Pharmaceutical Sciences. 2024; 9(1):1-9. DOI: http://dx.doi.org/10.20431/2455-1538.0901001.

**Copyright:** © 2024 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.